MB201 / Mustbio - LARVOL DELTA

MB201, a CD8+ T cell-selective anti-PD-L1 x IL-2 variant fusion protein, exhibits a potent anti-tumor efficacy without peripheral toxicity (AACR 2023) - "When administered to MC38 syngeneic mice, MB201 showed superior anti-tumor efficacy without both body weight reduction and lung weight gain compared to the avelumab monotherapy or combination therapy with rhIL-2. These preclinical observations support that MB201 has characteristics of a superb safety profile and excellent anti-tumor efficacy, and it may offer an advantageous therapeutic strategy for the treatment of cancer."

Clinical • Oncology • CD8 • IL2